PureTech Health plc (PTCHF)
USD 2.2
(0.0%)
USD 2.2
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 25.51 Million USD | -45.57% |
| 2022 | 46.87 Million USD | -9.9% |
| 2021 | 52.02 Million USD | -32.1% |
| 2020 | 76.62 Million USD | 94.98% |
| 2019 | 39.29 Million USD | 217.77% |
| 2018 | 12.36 Million USD | 65.89% |
| 2017 | 7.45 Million USD | 7.22% |
| 2016 | 6.95 Million USD | 40.32% |
| 2015 | 4.95 Million USD | -28.68% |
| 2014 | 6.94 Million USD | 63.14% |
| 2013 | 4.25 Million USD | 191.91% |
| 2012 | 1.45 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 124.73 Million USD | 16.03% |
| 2024 Q1 | 124.73 Million USD | 388.93% |
| 2023 Q1 | 126.08 Million USD | 168.99% |
| 2023 Q3 | 132.1 Million USD | 416.53% |
| 2023 Q2 | 25.57 Million USD | -79.71% |
| 2023 FY | 25.51 Million USD | -45.57% |
| 2023 Q4 | 25.51 Million USD | -80.69% |
| 2022 Q1 | 43.46 Million USD | -16.46% |
| 2022 Q2 | 48.09 Million USD | 10.66% |
| 2022 FY | 46.87 Million USD | -9.9% |
| 2022 Q3 | 41.89 Million USD | -12.88% |
| 2022 Q4 | 46.87 Million USD | 11.87% |
| 2021 FY | 52.02 Million USD | -32.1% |
| 2021 Q2 | 77.58 Million USD | 4.67% |
| 2021 Q3 | 48.79 Million USD | -37.1% |
| 2021 Q1 | 74.12 Million USD | -3.26% |
| 2021 Q4 | 52.02 Million USD | 6.61% |
| 2020 Q1 | 35.39 Million USD | -9.94% |
| 2020 Q3 | 73.36 Million USD | 90.77% |
| 2020 Q4 | 76.62 Million USD | 4.45% |
| 2020 FY | 76.62 Million USD | 94.98% |
| 2020 Q2 | 38.45 Million USD | 8.66% |
| 2019 Q3 | 36.36 Million USD | -43.74% |
| 2019 FY | 39.29 Million USD | 217.77% |
| 2019 Q2 | 64.64 Million USD | 1.8% |
| 2019 Q1 | 63.5 Million USD | 413.49% |
| 2019 Q4 | 39.29 Million USD | 8.05% |
| 2018 Q1 | 12.43 Million USD | 66.83% |
| 2018 FY | 12.36 Million USD | 65.89% |
| 2018 Q4 | 12.36 Million USD | 2.97% |
| 2018 Q3 | 12.01 Million USD | -3.43% |
| 2018 Q2 | 12.43 Million USD | 0.0% |
| 2017 Q1 | 7.32 Million USD | 5.28% |
| 2017 FY | 7.45 Million USD | 7.22% |
| 2017 Q4 | 7.45 Million USD | 0.0% |
| 2017 Q3 | 7.45 Million USD | 1.84% |
| 2017 Q2 | 7.32 Million USD | 0.0% |
| 2016 Q1 | 5.42 Million USD | 9.38% |
| 2016 FY | 6.95 Million USD | 40.32% |
| 2016 Q4 | 6.95 Million USD | 0.0% |
| 2016 Q3 | 6.95 Million USD | 28.28% |
| 2016 Q2 | 5.42 Million USD | 0.0% |
| 2015 Q3 | 4.95 Million USD | 48.84% |
| 2015 FY | 4.95 Million USD | -28.68% |
| 2015 Q4 | 4.95 Million USD | 0.0% |
| 2015 Q2 | 3.32 Million USD | 0.0% |
| 2015 Q1 | 3.32 Million USD | -52.09% |
| 2014 Q4 | 6.94 Million USD | 0.0% |
| 2014 Q3 | 6.94 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | 6.94 Million USD | 63.14% |
| 2013 FY | 4.25 Million USD | 191.91% |
| 2012 FY | 1.45 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 38.082% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -518.929% |
| SQZ Biotechnologies Company | 27.47 Million USD | 7.131% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 41.18% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 14.295% |
| Mesoblast Limited | 118.7 Million USD | 78.507% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -2590.37% |
| Genus plc | 233.1 Million USD | 89.055% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -770.601% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1798.802% |
| Marizyme, Inc. | 18.71 Million USD | -36.3% |
| ContraFect Corporation | 2.88 Million USD | -785.526% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -3301.6% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -18729.851% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1663.926% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -996.84% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -350.873% |
| MultiCell Technologies, Inc. | 202.58 USD | -12593443.292% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 55.623% |
| EV Biologics, Inc. | 1.49 Million USD | -1606.773% |
| Q BioMed Inc. | 4.1 Million USD | -520.733% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 22.927% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -3949.029% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1976.914% |
| Biomind Labs Inc. | 735.54 Thousand USD | -3368.463% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 85.128% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -96.292% |
| Skye Bioscience, Inc. | 4.61 Million USD | -452.774% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -2772.766% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -17927.389% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -334.536% |
| IMV Inc. | 28.88 Million USD | 11.674% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -99095.148% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1029.659% |
| GB Sciences, Inc. | 1.75 Million USD | -1350.116% |
| Alpha Cognition Inc. | 1.22 Million USD | -1990.51% |
| HST Global, Inc. | 98.31 Thousand USD | -25848.189% |
| CSL Limited | 12.18 Billion USD | 99.791% |
| Halberd Corporation | 150 Thousand USD | -16908.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -2460.577% |
| Resverlogix Corp. | 6.49 Million USD | -293.037% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -5242.827% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -9881.533% |
| argenx SE | 20 Million USD | -27.56% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 44.004% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -841.853% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -249406.112% |
| Genscript Biotech Corporation | 417.73 Million USD | 93.893% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -12616.832% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -964.009% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -11026.472% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 62.284% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -743.04% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -6992.38% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -25.502% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -17062.0% |
| BioStem Technologies, Inc. | 4.71 Million USD | -441.493% |
| ONE Bio Corp. | 19.71 Million USD | -29.404% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -10097.376% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -10157.317% |
| Agentix Corp. | 50 Thousand USD | -50924.0% |
| LadRx Corporation | 33.6 Thousand USD | -75815.015% |
| Cell Source, Inc. | 9.25 Million USD | -175.681% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -3273.693% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -3273.693% |
| NovAccess Global Inc. | 2.19 Million USD | -1059.7% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -260.705% |
| Itoco Inc. | 228.37 Thousand USD | -11071.002% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -11992.428% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -411.981% |
| Kadimastem Ltd | 891.22 Thousand USD | -2762.574% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -6248.653% |
| CytoDyn Inc. | 30.07 Million USD | 15.175% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -5167.983% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -7150.879% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -226.242% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -20726.122% |
| Rebus Holdings, Inc. | 310 Thousand USD | -8129.677% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -438.764% |
| International Stem Cell Corporation | 4.17 Million USD | -510.627% |
| Bioxytran, Inc. | 1.92 Million USD | -1225.299% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -40776.1% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1069.792% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -206.782% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -197.169% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1540.138% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -9419.403% |
| Neutra Corp. | 54.15 Thousand USD | -47008.354% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -1294.098% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1983.929% |
| IXICO plc | 472.02 Thousand USD | -5304.821% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -64.583% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 59.025% |
| CSL Limited | 12.18 Billion USD | 99.791% |
| Cellectis S.A. | 92.77 Million USD | 72.502% |